Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Purchased via two affiliated funds (Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.) at $11.173/share on Sept 4 and $10.6271/share on Sept 8. Sequential cluster buy of ~$10.7M gross (also sold 96,131 shares at $10.55 on Sept 8, net purchase ~$9.7M). Current price $9.80 = −9.8% below avg cost basis.
Direct purchase of 235,000 shares at ~$0.19/share (Sept 3–4) and indirect purchase via Ault & Co. of 1,913,691 shares at $0.1889/share (Sept 4). Ault has a longstanding pattern of frequent open-market accumulation. Current price $0.2014 = +6.6% above avg cost basis.
AIThe day in insider buying
SEC Form 4 Insider Scan — September 10, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (509 total Form 4s filed Sep 9–10). 2 qualifying buys (≥ $250K, transaction type P, open-market) totalling $11.1M.
Headline filings
ALMS — Srinivas Akkaraju (Director / 10% Owner) bought 986,721 shares ≈ $10.7M at $10.87 avg (across Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.); now $9.80 (−9.8% since buy). (filing)
GPUS — Milton C. Ault III (Executive Chairman) bought ~2.15M shares ≈ $406K at $0.189 avg (direct + via Ault & Co.); now $0.2014 (+6.6% since buy). (filing)
Notes
ALMS (Alumis Inc.) — Cluster buy across two funds. Srinivas Akkaraju (managing partner, Samsara BioCapital) made back-to-back purchases on Sept 4 ($11.17 avg) and Sept 8 ($10.63 avg) through two affiliated funds for a combined ~$10.7M gross outlay. With ALMS now at $9.80, the insider is about 10% underwater — but the sequential buying despite a falling price signals strong conviction. Alumis is a precision dermatology biotech developing selective TYK2 inhibitors (competing in the same pathway as Sotyktu/deucravacitinib). No catalyst announced concurrent with the purchases.
GPUS (Hyperscale Data Inc.) — Repeat buyer continues accumulation. Milton Ault III (formerly of Ault Alliance / BitNile) purchased ~2.15M Class A shares on Sept 3–4 at an average of ~$0.189, split between a direct account (~235K shares) and Ault & Co. (~1.91M shares). GPUS is now at $0.2014, putting Ault modestly in the green (+6.6%). This follows a well-established pattern of Ault personally accumulating shares in his own micro-cap GPU/data-center holding company.
Sector themes: Pharma/biotech (ALMS) and micro-cap GPU infrastructure (GPUS). The low total qualifying-buy count (2 out of 509 filings) reflects a market where most Form 4 activity this session was RSU vesting, option exercises, 10b5-1 plan sales, and small token buys below the $250K bar.
Most-bought stocks, last 30 days
RSG$333M · 3 buys, 3 insidersRepublic Services, Inc.
MAIR$220M · 2 buys, 2 insidersMadison Air Solutions Corp
BABA$51.4M · 5 buys, 3 insidersAlibaba Group Holding Ltd
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.